Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Apr 6;11(4):490.
doi: 10.3390/cancers11040490.

Targeting Tyrosine Kinases in Cancer: Lessons for an Effective Targeted Therapy in the Clinic

Adriano Angelucci  1
Affiliations
Editorial

Targeting Tyrosine Kinases in Cancer: Lessons for an Effective Targeted Therapy in the Clinic

Adriano Angelucci. Cancers (Basel). .

Abstract

The 21st century has finally seen the full achievement of targeted therapy to treat cancer with the promise of lower side effects and improved efficacy with respect to cytotoxic chemotherapeutics [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Targeted drugs approved for cancer were classified according to target type. TK: Tyrosine Kinase; STK: Serine Threonine Kinase; CAA: Cancer Associated Antigen; GM: Genome Maintenance; HP: Hormone Pathway; CS: Cytokine Signaling; IC: Immunological Checkpoint.
Figure 2
Figure 2
Tyrosine kinases targeted for different cancers by drugs approved in the clinic. The color gradient (from green to red) indicates the abundancy of the target for each cancer (right) or the frequency of the same target in different cancers (bottom).
See this image and copyright information in PMC

References

    1. National Cancer Institute; 2019. [(accessed on 14 March 2019)]. Targeted cancer Therapies. Available online: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/t....
    1. Wishart D.S., Knox C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., Chang Z., Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34:D668–D672. doi: 10.1093/nar/gkj067. - DOI - PMC - PubMed
    1. U.S. National Library of Medicine; 2019. [(accessed on 14 March 2019)]. ClinicalTrials.gov. Available online: https://clinicaltrials.gov.
    1. Donoghue J.F., Kerr L.T., Alexander N.W., Greenall S.A., Longano A.B., Gottardo N.G., Wang R., Tabar V., Adams T.E., Mischel P.S., et al. Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response. Cancers (Basel) 2018;10:243. doi: 10.3390/cancers10080243. - DOI - PMC - PubMed
    1. Kozaki R., Vogler M., Walter H.S., Jayne S., Dinsdale D., Siebert R., Dyer M.J.S., Yoshizawa T. Responses to the Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines. Cancers (Basel) 2018;10:127. doi: 10.3390/cancers10040127. - DOI - PMC - PubMed

Publication types

LinkOut - more resources